Upadacitinib 15 mg showed efficacy through 1 year in Ankylos
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to report the efficacy and safety of upadacitinib through 1 year in patients with ankylosing spondylitis (AS).

In the SELECT-AXIS 1 study, adults with active AS and inadequate response to non-steroidal anti-inflammatory drugs were randomized to upadacitinib 15 mg once daily (QD) or placebo. At week 14, patients continued in the open-label extension and received upadacitinib up to week 104; reported here are interim data up to week 64.

--Of 187 patients, 178 completed week 14 on study drug and entered the open-label extension.

--Similar proportions of patients in either group (continuous upadacitinib or placebo-to-upadacitinib) achieved Assessment of SpondyloArthritis international Society (ASAS) 40 or Ankylosing Spondylitis Disease Activity Score (ASDAS) low-disease activity at week 64: more than 70% of patients achieved these endpoints based on non-responder imputation (NRI) and more than 81% based on as-observed (AO) analyses.

--Furthermore, more than 34% (NRI) and more than 39% (AO) of patients achieved ASDAS inactive disease or ASAS partial remission at week 64.

--Mean changes from baseline to week 64 in pain, function, and inflammation showed consistent improvement or sustained maintenance through the study. Among 182 patients receiving upadacitinib, 618 adverse events were reported.

In particular, Upadacitinib 15 mg of QD was shown in 1 year to be sustainable and consistent. The efficacy of patients changing from placebo to upadacitinib at week 14 was similar compared to patients receiving continuous upadacitinib.

Source: https://onlinelibrary.wiley.com/doi/10.1002/art.41911